I'm in total agreement with you Pineywoods, regarding the technology. I love the Actipatch, use it daily and will continue to for the foreseeable future. What I'm less sure about is who's going to be successful, from an investors standpoint, at bringing it to market? BIEL doesn't exclusivity on this and their patent is running out. They need to ramp this up now or face challenges from deep pocketed companies who will pounce on this once the patent expires.

It'll be interesting to see how the company responds when the FDA finally approves for women and hopefully for Recovery RX. I am currently of the mindset that they are building a solid foundation behind the scenes, preparing for a full roll out in the U.S. very soon after the FDA clearance.

Atlas1